BRIEF—Biocon Biologics secures cGMP for Indian facility

Biocon subsidiary Biocon Biologics has received a European Union certificate of Good Manufacturing Practice (cGMP) for its Bengaluru, India-based facility.

The site, which was completed in 2021, will be used to manufacture monoclonal antibodies, and was assessed by EU inspectors in April 2022.

Biocon said: “This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing,” adding that it was “awarded the Facility of the Year Award with an Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE).”